Dr. Michael J. Maresca, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 946
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 219661
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vassar Brothers Medical Center Poughkeepsie, NY
- Westchester Medical Center Valhalla, NY
- Canton-Potsdam Hospital Potsdam, NY
- Slhs Massena, Inc Massena, NY
- Gouverneur Hospital Gouverneur, NY
Medical groups
- North Shore Hematology Oncology Associates PC (479 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 946
- Services billed
- 157,138
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 20,790 | 46 |
| Injection, pembrolizumab, 1 mg | 14,208 | 17 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 10,710 | 15 |
| Injection, fosaprepitant, 1 mg | 7,804 | 12 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,900 | 33 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,907 | 55 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,771 | 557 |
| Injection, palonosetron hcl, 25 mcg | 1,480 | 39 |
| Lactate dehydrogenase (enzyme) level | 1,115 | 441 |
| Magnesium level | 1,082 | 426 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Poughkeepsie, NY | 130 |
| Xarelto (rivaroxaban) Other prescribers in Poughkeepsie, NY | 83 |
| Warfarin Sodium Other prescribers in Poughkeepsie, NY | 50 |
| Aranesp (darbepoetin alfa in polysorbat) | 40 |
| Prednisone Other prescribers in Poughkeepsie, NY | 34 |
| Revlimid (lenalidomide) | 28 |
| Darzalex Faspro (daratumumab-hyaluronidase-fihj) | 27 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Poughkeepsie, NY | 27 |
| Hydroxyurea Other prescribers in Poughkeepsie, NY | 25 |
| Akynzeo (fosnetupitant/palonosetron) | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 15 payments worth $444 in total to this clinician.
| Aveo Pharmaceuticals, Inc. | $99.00 |
|---|---|
| EMD Serono, Inc. | $73.44 |
| Pfizer Inc. | $69.89 |
| Incyte Corporation | $49.99 |
| Menarini Silicon Biosystems, Inc. | $29.81 |
| Daiichi Sankyo Inc. | $29.02 |
| Celgene Corporation | $27.68 |
| Eisai Inc. | $24.74 |
| Food and Beverage | $295 |
|---|---|
| Education | $149 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Oct 15, 2025 | Education FOTIVDA · Oncology · in-kind | $99.00 |
| Incyte Corporation Dec 4, 2025 | Education | $49.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.